IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
FDA Approves Saphris for acute psychosis
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Mon, 17 Aug 2009 08:31:56 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (11 lines) 
Schering-Plough Announces FDA Approval of Saphris
 From PR Newswire - Aug 14, 2009
KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough 
Corporation today announced that the U.S. Food and Drug 
Administration has approved Saphris (asenapine) sublingual tablets 
for acute treatment of schizophrenia in adults and acute treatment of 
manic or mixed episodes associated with bipolar  I disorder with or 
without psychotic features in adults.

www.peoplewho.org

ATOM RSS1 RSS2